---
layout: post
title: New Drug Approvals 2012 - Pt. XI - Taliglucerase alfa (ElelysoTM)
date: '2012-05-07T19:56:00.001+01:00'
author: felix
tags:
- Parenteral Drugs
- Enzyme drugs
- 2012 New Drugs
modified_time: '2013-01-02T09:38:46.320Z'
thumbnail: http://4.bp.blogspot.com/-shp5idbgiDY/UOQAF3_pBmI/AAAAAAAAClA/4XlIlfbDpZk/s72-c/images-1.jpeg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-1224906620023862722
blogger_orig_url: http://chembl.blogspot.com/2012/05/new-drug-approvals-2012-pt-xi.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-shp5idbgiDY/UOQAF3_pBmI/AAAAAAAAClA/4XlIlfbDpZk/s1600/images-1.jpeg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/-shp5idbgiDY/UOQAF3_pBmI/AAAAAAAAClA/4XlIlfbDpZk/s1600/images-1.jpeg" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<center face="arial">
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/2,0,0,0,1,0,1,0,0" width="400" /></center>
<center face="arial">
<br />
</center>
<center face="arial">
<b>ATC code</b>:<span class="Apple-style-span" style="font-family: inherit;">&nbsp;<a href="http://www.whocc.no/atc_ddd_index/?code=A16AB11"><span class="Apple-style-span" style="line-height: 18px;">A16AB11</span></a></span></center>
<center face="arial">
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;"><b>Wikipedia</b>: <a href="http://en.wikipedia.org/wiki/Taliglucerasealfa">Taliglucerase alfa</a></span></span></center>
<center face="arial">
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">&nbsp;</span></span></center>
<br />
<div style="text-align: left;">
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">On May 1, the FDA approved taliglucerase alfa for the treatment of Type I Gaucher's disease. Gaucher's disease is the most common of the <a href="http://en.wikipedia.org/wiki/Lysosomal_storage_disease">lysosomal storage diseases</a>. It is a hereditary disease caused by a deficiency of the enzyme </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">β-</span></span>glucocerebrosidase (Uniprot: <a href="http://www.uniprot.org/uniprot/P04062">P04062</a>), also called β-Glucosidase. Gaucher's disease is a rare genetic disease with an incidence of 1 in 50,000 births and is considered an orphan disease. <span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">Type I Gaucher's disease is about 100 times more common in people of <a href="http://en.wikipedia.org/wiki/Ashkenazi_Jews">Ashkenazi</a> jewish descent compared a north American population. </span></span>Symptoms of type I Gaucher's disease begin typically in early adulthood and include enlarged liver and grossly enlarged spleen, impaired bone structure, anemia and low platelet levels, leading to prolonged bleeding and easy bruising. If enzyme replacement therapy (ERT) is available, the prognosis for patients with type I Gaucher's disease is good.<br />
<br /></div>
<div style="text-align: left;">
</div>
<div style="text-align: left;">
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">β-</span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">Glucocerebrosidase is an enzyme of 536 amino acids and molecular weight of approximately 59.7 kDa. The gene for </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">β-</span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">glucocerebrosidase is located on the first chromosome </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">(1q21) and catalyzes the hydrolyzation of <a href="http://en.wikipedia.org/wiki/Glucocerebroside">glucocerebrosides</a> (eg. </span></span><a href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:18368"><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">ChEBI:18368</span></span></a><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">), a process required for the turnover of the cellular membranes of red and white blood cells.&nbsp; </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">Macrophages clearing these cells</span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;"> fail to metabolize the lipids, accumulating them instead in their lysosomes.&nbsp; Thus, macrophages turn into dysfunctional Gaucher cells and abnormally secrete inflammatory signals. The deficiency of glucocerebrosidase in Type I Gaucher's disease is only partial and in most cases caused by a mutation&nbsp;</span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;"> replacing asparagine with serine in the 370<sup>th</sup> residue of the protein sequence. The deficiency of the mutant enzyme can be compensated by injection of an exogenous replacement and drastically improve the prognosis for patients with type I Gaucher disease. Prior to the approval of taliglucerase alfa, <a href="http://en.wikipedia.org/wiki/Imiglucerase">imiglucerase</a> and <a href="http://chembl.blogspot.co.uk/2010/04/2010-new-drug-approvals-pt-iv.html">velaglucerase alfa</a> were already available ERTs for type I Gaucher's disease. </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">The graphic below illustrates the reaction catalyzed by </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">β-</span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">glucocerebrosidase and ERTs. </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">The enzyme classification code for </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">β-</span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">glucocerebrosidase is <a href="http://enzyme.expasy.org/EC/3.2.1.45">3.2.1.45</a>.</span></span><br />
<br />
<br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="http://3.bp.blogspot.com/-XsxahV5gI-w/T6buP7rBBaI/AAAAAAAAAdY/IrWfL2wgEeg/s1600/taliglucerase_alfa.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" height="320" src="http://3.bp.blogspot.com/-XsxahV5gI-w/T6buP7rBBaI/AAAAAAAAAdY/IrWfL2wgEeg/s320/taliglucerase_alfa.png" width="260" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><br /></td></tr>
</tbody></table>
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">&nbsp;Taliglucerase alfa </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">is  a monomeric glycoprotein containing 4 N- linked glycosylation sites and </span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">has a molecular weight of 60,8 kDa</span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">. The recombinant enzyme differs from native human  glucocerebrosidase by two amino acids at the N terminal and up to 7  amino acids at the C terminal. Taliglucerase alfa is decorated with mannose-terminated oligosaccharide chains that are specifically recognized by macrophage receptors and assist in 'homing' the enzyme to its target cells.</span></span><span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;"><br />
</span></span><br />
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">Taliglucerase alfa is the first ERT <a href="http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0004792">expressed in plant cells</a> (carrot root cells), not mammalian cells. Cultures of plant cells are more cost-effective for the expression of recombinant enzymes.&nbsp;</span></span><br />
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;"><br />
</span></span><br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="http://3.bp.blogspot.com/-P4TEO2qiBgA/T6b6gQEMeSI/AAAAAAAAAdk/PwvjlKFV7uU/s1600/glucocerebrosidase.png" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" height="201" src="http://3.bp.blogspot.com/-P4TEO2qiBgA/T6b6gQEMeSI/AAAAAAAAAdk/PwvjlKFV7uU/s320/glucocerebrosidase.png" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Crystal structure of the human glucocerebrosidase (PDBe <a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1ogs/summary.html">1ogs</a>). </td></tr>
</tbody></table>
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;"><br />
</span></span><br />
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">The recommended dose is 60 Units/kg of body weight administered once every 2 weeks as a 60-120 minute intravenous infusion. A Unit is the amount of enzyme that catalyzes the hydrolysis of 1 micromole of the synthetic substrate para-nitrophenyl-β-D-glucopyranoside (pNP-Glc) per minute at 37°C. Adverse effects include pharyngitis, headache, arthralgia, flu and back pain.</span></span><br />
<br />
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">Taliglucerase alfa is marketed by <a href="http://www.pfizer.com/products/rx/rx_product_elelyso.jsp">Pfizer</a> and <a href="http://www.protalix.com/product-development/elelyso.asp">Protalix</a> under the brand name <a href="http://www.elelyso.com/index.aspx">Elelyso</a>.&nbsp;</span></span><br />
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;"><br /></span></span>
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;">The full prescribing information can be found <a href="http://labeling.pfizer.com/ShowLabeling.aspx?id=798">here</a>.<br />
</span></span><br />
<span class="Apple-style-span" style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 18px;"><br />
</span></span></div>
